De-novo AI-proteins
Deleting the Undruggable



ProtOS is an AI-first protein design company developing therapeutics to treat undruggable diseases.
Mission.
Our foundation models generate AI-proteins that go beyond the limits of small molecule drugs. By harnessing nature’s protein ingenuity, yet engineering it to perform novel functions - ProtOS is creating a paradigm shift in drug development, from accidental discovery to intentional design.
​
Technology.
De-novo AI-Proteins
Our transformative approach to protein design leverages proprietary AI models to create novel bio-therapeutics that target previously undruggable pathways, by precisely interacting with proteins-of-interest beyond the reach of small molecules and antibodies.

Targeted Protein Degradation

ProtOS has created a robust therapeutic platform to develop Biologic Targeted Protein Degraders. Our SHRED platform uses foundation models to design de-novo AI-proteins that are highly specific and effective in degrading undruggable targets, offering significant advantages over existing PROTAC and Molecular-Glue approaches.
AI-first Pharma Company
ProtOS is backed by a team of world-leading scientists and AI experts. Combining foundational models, bioinformatics, and structural biology, we create the next generation of bio-therapeutics. End-to-end, from target selection and mechanism-of-action elucidation, to the generation of drugs that are safe and effective by design.


Team.
Leadership

Ofer Springer
CTO, President and Co-founder
Ofer is the former Chief Scientist of Mobileye (NASDAQ:MBLY), and an expert in Computer Vision, Machine Learning, and AI. He has developed technologies that have become strategic growth drivers for Mobileye. Ofer holds a Ph.D. in Machine Learning from the Hebrew University and Weizmann Institute, and an MSc in Physics. He is an inventor of over 20 issued patents.

Yossi Pollak
CEO and Co-founder
Yossi co-founded and led Sight Diagnostics for 12 years, taking it from idea to a 300 people company, raising $200M, and securing FDA clearance for the company’s AI-based blood test. Prior to that, Yossi was an algorithm developer and project leader at Mobileye (NASDAQ:MBLY). Yossi holds an MBA with distinction from INSEAD Business School, and a B.Sc. in Mathematics, magna cum-laude, from the Hebrew University.

Yochay Eshel
VP R&D
Yochay is the former EVP R&D of Sight Diagnostics, where he spearheaded the development of AI-powered medical devices, secured FDA clearances, and led large-scale research initiatives. He has managed multidisciplinary teams across AI, computer vision, physics, and biology in highly regulated environments. Yochay holds an M.Sc. in Physics from the Weizmann Institute and a B.Sc. in Physics from the Hebrew University.

Extended Team

Chaja Katzman
Synthetic Biology Expert
Chaja Katzman is a PhD student at The Nissim Lab for Synthetic Biology, where her research focuses on synthetic gene circuits and cancer biology. She specializes in Synthetic Promoters with Enhanced Cell-State Specificity (SPECS), a cutting-edge approach that enables precise, cell-state-specific gene expression. Chaja's work contributes to next-gen cancer therapies, immunotherapies, and innovative therapeutics development.

Lior Nissim
Synthetic Biology Expert
​Dr. Lior Nissim is an Assistant Professor who heads The Biomedical Synthetic Biology Lab at the Hebrew University of Jerusalem. His work is at the forefront of developing innovative synthetic biology platforms to address complex biomedical and biotechnological challenges. Dr. Nissim has received the Kaye Innovation Award for his pioneering contributions.

Arnon Houri-Yafim
Senior Market Analyst
Arnon Houri-Yafin is the CEO of Zzapp, a software company that supports anti-malaria operations and focuses on cost-effectiveness. Before that, Arnon was Director of Research at Sight Diagnostics, a statistics lecturer at the Hebrew University, and a junior researcher at the Israel Securities Authority in the context of stock market regulation.

Advisory Board.

Prof. Aaron Ciechanover
Nobel Laureate for discovering the Uniquitination Mechanism
Prof. Aaron Ciechanover is a Distinguished Research Professor at the Technion – Israel Institute of Technology in Haifa, Israel. He was awarded the Nobel Prize in Chemistry in 2004 for the discovery of ubiquitin-mediated protein degradation, which has a critical role in maintaining the homeostasis of cells.

Prof. David Rubenzstein
Autophagy Degradation Mechanism Authority
David Rubinsztein is Professor of Molecular Neurogenetics and a UK Dementia Research Institute Group Leader at the University of Cambridge. He is Deputy Director of the Cambridge Institute for Medical Research. His research is focused in the field of autophagy, particularly in the context of neurodegenerative diseases, where his lab pioneered the strategy of autophagy upregulation as a possible therapeutic approach.